ZIOPHARM Oncology Inc (ZIOP)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

ONE FIRST AVENUE BOSTON, MA 02129

ZIOPHARM Oncology, Inc. is a biopharmaceutical company seeking to acquire, develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer drugs that address unmet medical needs. The Company is conducting U.S. studies for its two product candidates, ZIO-101 and ZIO-201.

Data as of 2020-06-27
Market Cap730.716 Million Shares Outstanding214.286 Million Avg 30-day Volume2.398 Million
P/E Ratio Dividend Yield EPS-0.69
Price/Sales Price cash flow ratio42.4 Price free cash flow ratio-19.2
Book Value0.84 Price to Tangible Book4.41 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.226622
BETA2.51543 52-week High/Low7.25 / 1.795 Stddev0.225423
View SEC Filings from ZIOP instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 145 32 (2.1%)
Aggregate 13F shares on 03/31/2020: 98.995 Million 62.877 Million
Aggregate 13F shares on 12/31/2019: 85.122 Million 51.043 Million
Percent change: 16.30% 23.18%
Funds creating new positions: 25 8
Funds Adding to an existing position: 52 12
Funds closing out their position: 26 9
Funds reducing their position: 33 7
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ZIOP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ZIOP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LEBEL FRANCOIS CHIEF MEDICAL OFFICER

  • Officer
299,955 2020-06-22 0

BRAUNSTEIN SCOTT

  • Director
0 2020-06-09 1

WEISER MICHAEL

  • Director
0 2020-06-08 0

PAGAN DOUGLAS W. CHIEF FINANCIAL OFFICER

  • Officer
0 2020-06-01 1

BOWDEN CHRISTOPHER

  • Director
0 2020-05-21 3

FOWLER WYCHE

  • Director
84,287 2020-05-20 0

KIRK RANDAL J

  • 10% Owner
0 2020-05-14 0

ABERCROMBIE GEORGE B

  • Director
0 2020-05-12 0

HAGEN HEIDI

1,750 2020-04-29 1

SCHWARTZ BRIAN

  • Director
6,000 2020-03-05 0

AMELLO JASON SVP, CFO & TREASURER

144,642 2020-02-28 0

LAFOND KEVIN G SVP, TREASURER & CAO

  • Officer
81,985 2020-01-29 3

COOPER LAURENCE JAMES NEIL CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
1,904,973 2020-01-29 2

MAUNEY DAVID M MD PRESIDENT

  • Officer
275,778 2020-01-29 2

HADFIELD ROBERT GENERAL COUNSEL AND SECRETARY

  • Officer
159,819 2020-01-29 2

DE GROOT ELEANOR EVP, GM CELL THERAPY

  • Officer
228,033 2020-01-29 2

BUCK JILL EVP, GM GENE THERAPY

  • Officer
227,410 2020-01-29 2

SHUKLA SATH EVP, CHIEF FINANCIAL OFFICER

  • Officer
80,500 2020-01-29 3

TARRIFF SCOTT CEO

  • Officer
  • Director
  • 10% Owner
1,550,954 2020-01-23 1

EZICKSON ELAN

  • Director
71,887 2019-12-31 1

KIRK RANDAL J

INTREXON CORP

  • 10% Owner
0 2019-12-13 0

CANNON JAMES ANTHONY

  • Director
398,050 2019-05-07 0

BELBEL CAESAR J COO, CLO, AND SECRETARY

  • Officer
207,434 2017-12-29 0

BRENNAN MURRAY

  • Director
72,620 2017-12-29 0

MCINERNEY TIMOTHY

  • Director
0 2017-05-18 0

YOUSSOUFIAN HAGOP CHIEF MEDICAL OFFICER

  • Officer
0 2015-03-07 0

LEWIS JONATHAN CEO

  • Officer
  • Director
744,145 2014-12-30 0

BAGLEY RICHARD E PRESIDENT, COO & TREASURER

  • Officer
  • Director
211,239 2011-12-30 0

FRAGIN GARY S

  • Director
67,500 2010-03-31 0

ESSEX WOODLANDS HEALTH VENTURES FUND VI L P

  • 10% Owner
2,371,642 2009-09-15 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments